Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus rituximab vs placebo plus rituximab in treatment-naive follicular lymphoma
2016-003202-14Phase 3Unknown
- Sponsor
- Pharmacyclics
- Start
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ibrutinib in follicular lymphoma (FL), sponsored by Pharmacyclics. Status: unknown.
02
Drugs
ibrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2016-003202-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003202-14.